News

June 2, 2020June 2, 2020

Breastfeeding Lowers Risk of Ovarian Cancer for Decades, Study Finds

News

Women who breastfeed are at a significantly lower risk of developing ovarian cancer overall and some of its subtypes, including the deadliest — high-grade serous tumors, a large data study reported. ... Read more

May 27, 2020May 27, 2020

Phase 2 Trial to Test Exercise as Way to Improve Quality of Life in Recurring Ovarian Cancer

News

A new Phase 2 clinical trial in Australia will assess whether exercise can improve the quality of life and physical function of women with recurring ovarian cancer who are on chemotherapy. ... Read more

May 20, 2020May 20, 2020

SOLO-2 Results: Maintenance Therapy with Lynparza Extends Survival in Relapsed Ovarian Cancer

News

Maintenance therapy with AstraZeneca’s Lynparza (olaparib) extended survival by more than one year in women with BRCA-mutated relapsed ovarian cancer, whose tumors responded to platinum-based chemotherapy, final results from the ... Read more

May 13, 2020May 13, 2020

Zejula-Avastin Combo Treating Advanced Cancer Patients in Phase 2 Trial

News

Zejula (niraparib) given in combination with Avastin (bevacizumab) shows promising safety and efficacy at delaying disease progression in women with advanced ovarian cancer who had responded to a first-line platinum-based chemotherapy ... Read more

May 12, 2020January 12, 2021

FDA Approves Lynparza Combo as First-line Maintenance Therapy for Advanced Ovarian Cancer

News

The U.S. Food and Drug Administration (FDA) has approved Lynparza (olaparib), in combination with bevacizumab, as a first-line maintenance therapy for women with advanced ovarian cancer positive for homologous recombination deficiency (HRD) and who responded to platinum-based chemotherapy. This ... Read more

May 6, 2020May 6, 2020

STRO-002 Continues to Show Promise in Advanced Ovarian Cancer, Early Trial Results Show

News

STRO-002, an investigational antibody-drug conjugate, continues to show promising safety and anti-tumor activity in women with advanced ovarian cancer, according to preliminary data from a Phase 1 clinical trial. The ... Read more

April 30, 2020May 12, 2020

FDA Approves Zejula as First-line Maintenance Therapy for Advanced Ovarian Cancer

News

The U.S. Food and Drug Administration (FDA) has approved Zejula (niraparib) as a first-line maintenance therapy for women with advanced ovarian cancer who responded to platinum-based chemotherapy, regardless of their BRCA mutation status. This indication ... Read more

April 29, 2020April 29, 2020

Ovarian Cancer Often More Advanced at Diagnosis in Rural Areas in US

News

Women living in rural areas in the U.S. are significantly more likely to have metastatic disease at the time of their ovarian cancer diagnosis than those living in metropolitan areas, ... Read more

April 28, 2020April 28, 2020

Surge in Telemedicine One ‘Good’ Outcome from COVID-19 Crisis, Doctors Say

News, syndicated

While there are few silver linings to the cloud created by COVID-19, the pandemic that has killed tens of thousands, hobbled economies worldwide and drove millions to quarantine in their ... Read more

April 22, 2020April 22, 2020

First Advanced Cancer Patients Dosed With VT1021 in Trial’s Expansion Phase

News

A Phase 1b/2 trial investigating Vigeo Therapeutics‘ VT1021 as a stand-alone treatment for advanced ovarian cancer and other tumor types has dosed the first patients in its dose expansion stage. Early ... Read more